Evidence map›Paper›PMID 32012228›Full record

Trial reportBritish journal of haematology2020

Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.

Diana Basali, Rajshekhar Chakraborty, Lisa Rybicki, Nathaniel Rosko, Janice Reed, Maryann Karam, Kristen Schlueter, Hayley Dysert, Matt Kalaycio, Jason Valent

Open access · hybridAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Epidemiology, Staging, and Management of Multiple Myeloma.Medical sciences (Basel, Switzerland) · 2021
    Review
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Diana BasaliDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0001-6984-9684
Rajshekhar ChakrabortyDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Lisa RybickiDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Nathaniel RoskoDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Janice ReedDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Maryann KaramDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Kristen SchlueterDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Hayley DysertDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Matt KalaycioDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Jason ValentDepartment of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax-based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non-haematologic toxicities, most commonly gastrointestinal upset, were observed.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicErythrocyte TransfusionMultiple MyelomaPlatelet TransfusionSulfonamidesTranslocation, GeneticAdultChromosomes, Human, Pair 11Chromosomes, Human, Pair 14FemaleHumansMaleProto-Oncogene Proteins c-bcl-2BCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclaxamyloidamyloidosisrelapsed/refractory multiple myelomatranslocationvenetoclax

Identifiers

PMID32012228
PMCPMC9291136
OpenAlexW3003588883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.